论文部分内容阅读
Objective To improve the vaccine potency of gene modified tumor cells Methods Using recombinant adenoviruses, we expressed the B7 1 gene in murine breast tumor cell line EMF 6 and a subline previously transfected with retrovirus vector XdF harboring the IL 2 TNFα fusion gene Results Immunization/challenge experiments demonstrated that IL 2 TNFα/B7 1 co modified tumor cells possessed a lower tumorigenicity in vivo and an improved tumor specific vaccine potency compared with single gene transfectant ( P <0 05) Three weeks after immunization with a variety of tumor cells, the mixed lymphocyte and tumor cells reaction assay (MLTB) and 51 Cr release assay were performed to test cellular immunity function The results indicated that IL 2 TNFα and B7 1 together induced a more potent antitumor immune response than either molecule alone, 25% higher than IL 2 TNFα and 20% higher than B7 1, respectively Conclusion The IL 2 TNFα fusion gene and B7 1 gene act in concert to improve their antitumor effectiveness
Objective To improve the vaccine potency of gene modified tumor cells Methods Using recombinant adenoviruses, we have expressed the B7 1 gene in murine breast tumor cell line EMF 6 and a subline previously transfected with retrovirus vector XdF harboring the IL 2 TNFα fusion gene Results Immunization / challenge experiments demonstrated that IL 2 TNFα / B7 1 co modified tumor cells possessed a lower tumorigenicity in vivo and an improved tumor specific vaccine potency compared with single gene transfectants (P <0 05) Three weeks after immunization with a variety of tumor cells, the mixed Lymphocyte and tumor cell reaction assay (MLTB) and 51 Cr release assay were performed to test cellular immunity function The results indicated that IL 2 TNFα and B7 1 together induced a more potent antitumor immune response than either molecule alone, 25% higher than IL 2 TNFα and 20% higher than B7 1, respectively Conclusion The IL 2 TNFα fusion gene and B7 1 g ene act in concert to improve their antitumor effectiveness